Reports to - Vice President of Research
ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases. We are committed to innovative drug development, leading the way with novel technologies to create new therapies that address the high unmet medical needs of patients suffering from serious infections for which there are limited available treatment options. The company is located in Westchester County, near New York City.
An opportunity is available to grow with us in an environment that is both challenging and energetic. ContraFect is seeking self-motivated and collaborative individuals to join our team and to contribute their talent and expertise. We are looking for positive individuals who will add to our committed and dedicated employee base and contribute to the development of novel therapeutic agents which have the potential to change the therapeutic landscape for treating serious infections.
It is an exciting time in our Company’s history. CF-301, our lead compound, is the first and only bacteriophage-derived lysin (cell wall hydrolase) to enter clinical trials in the US. CF-301, which targets Staphylococcus aureus, including MRSA, is the first of a new class of protein-based therapeutics for the treatment of serious bacterial infections. CF-301 is currently being studied in a multinational, multicenter Phase 2 clinical trial for the treatment of S. aureus bacteremia including endocarditis. In addition to CF-301, we have an exciting pre-clinical and discovery pipeline of lysins targeting anti-biotic resistant gram positive and gram negative bacteria. Our primary focus in on developing treatments for bacteria designated by CDC and the WHO as urgent or serious threats of critical or high priority.
In addition, we are developing a triple antibody therapy for the potential treatment for serious influenza infections. We are using ContraFect’s technical expertise to develop biotherapeutic products for infectious diseases that have high unmet medical needs, particularly products used in hospital-based markets.
The Director will provide an important leadership role in Microbiology by overseeing the day to day operation of the ContraFect Microbiology Laboratory and the performance of clinical microbiology development studies in the field of protein-based therapeutics to treat serious bacterial infections. The laboratory is a major site for the conduct of clinical microbiologic testing of our lead compound, CF-301, in support of marketing authorization applications (NDA/BLA, MAA), approval and eventual clinical use if approved. Together with the VP of Research, the Director of Clinical Microbiology will institute quality metrics, work flows, cycle times and actively strive to increase the efficiency of the lab and the timeliness and quality of reports delivered by the research scientists. The laboratory conducts a wide range of Research activities including lysin identification and characterization, antimicrobial susceptibility testing, time kill assays, synergy studies, molecular cloning, protein engineering and optimization, research scale protein production and purification, in vitro microbiologic profiling, as well as bioassays to support preclinical studies (e.g. ELISAs, etc.).
The Director will have a key role in working directly with the VP of Research in the planning and implementing of all laboratory processes and procedures in addition to the forecasting of resource and equipment needs and the reporting of results from in vitro microbiology studies. The Director will also have the opportunity to conduct hands on research in support of ContraFect’s Research efforts under the direction of the VP of Research, and is expected to publish and present at scientific meetings. The incumbent will be a key partner to the VP of Research and will work to continuously improve the technical performance of the lab across all domains, including the design, conduct and reporting of work conducted in the lab.
Importantly, the ContraFect Laboratory may also perform cell-based bioassays (e.g.lytic assay) as part of GMP drug substance and drug product release testing and stability protocols. The successful candidate will be responsible for ensuring quality and compliance in the conduct of the cell-based bioassay in accordance with the principles of GLP, in partnership with the Associate Director of Bioanalytics and Laboratory Operations, the VP of Research and the Quality team at ContraFect.
Education, Experience, Skills
post-graduate clinical microbiology experience in pharmaceutical or biotechnology setting or at a CRO
Respect. People matter.
Patient- Focus. Act with urgency and passion to save lives.
Leadership. Set high standards, and empower others to do the same.
Innovation. Challenge the status quo to deliver solutions.
Collaboration. Work together to achieve our vision.
Quality. Strive for excellence in all that we do.
Integrity. Courage to be honest, ethical, and transparent.
Salary: Commensurate with experience.
No phone calls, please.
Job Type: Full-time